Join to access to all OVN content. Join for Free
A Trip Around the MSL Insights Cycle
MSL insights insight cycle competitive intelligence training MSLs audience understanding

A Trip Around the MSL Insights Cycle


Share This Article


Summary

In this episode, Patrina Pellett and Richard Swank join Tom Caravela to explore the intricacies of the MSL insight cycle. They delve into the growth and insights course, highlighting common mistakes and the importance of training MSLs on inputting insights. The discussion covers the stages of the insight cycle, with a focus on competitive intelligence and the gathering stage. Patrina and Richard emphasize the significance of understanding your audience and effective mechanisms for sharing insights. The episode wraps up by debunking common myths about insights and includes a call to action for listeners.

In this week’s episode, Patrina Pellett and Richard Swank  (both from MSL Growth) join me to take a trip around the MSL Insights Cycle.

Click for Source
MSL insights, insight cycle, competitive intelligence, training MSLs, audience understanding

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Insight about INSIGHTS, and how they can help your MSL career!
Partner Avatar MSL Talk: Tom Caravela, Joe Liberman

Insight about INSIGHTS, and how they can help your MSL career!

Podcast
How to maximize KOL engagement and MSL insights gathering at your next virtual congress with Patrina Pellet
Partner Avatar MSL Talk: Tom Caravela, Patrina Pellet

How to maximize KOL engagement and MSL insights gathering at your next virtual congress with Patrina Pellet

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN